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Abstract
In the intestine, apoC-III delays chylomicron secretion, and causes a decrease in
chylomicron size. Once apoC-III is in circulation, apoC-III delays triglyceride-rich
remnants clearance by inhibiting lipoprotein lipase and liver low-density lipoprotein
receptor. In humans, high levels of plasma apoC-III directly result in
hypertriglyceridemia. ApoC-III is a critical cardiovascular risk factor, and humans
expressing null mutations in apoC-III are robustly protected from cardiovascular
disease. Because of its critical role in elevating plasma lipids and CVD risk, the factors
that regulate apoC-III expression in the liver have been determined, and include
glucose, insulin (through FoxO1), and dietary fat. Considerably less is known about the
factors that regulate intestinal apoC-III. This study utilizes primary murine enteroids,
Caco-2 cells, and dietary studies in wild-type mice to show that intestinal apoC-III
expression does not change in response to fatty acids, glucose, or insulin
administration, in contrast to hepatic apoC-III. Intestinal apoC-III is not sensitive to
changes in FoxO1 expression (which is itself very low in the intestine, as is FoxO1
target IGFBP-1), nor is intestinal apoC-III responsive to western diet, a significant
contrast to hepatic apoC-III stimulation during western diet. These data strongly suggest
that intestinal apoC-III is not a FoxO1 target. These data support the idea that apoC-III
is not regulated coordinately with hepatic apoC-III, and establishes another key aspect
of apoC-III that is unique in the intestine and different from the liver.
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Introduction
Hyperlipidemia is central to pathophysiological development of atherosclerosis,
the key component of coronary artery disease, a form of cardiovascular disease (CVD).
CVD is the leading cause of death worldwide.1 Because atherosclerosis develops with
the uptake of LDL cholesterol (LDL-C) by the vascular endothelium,2 strategies to
prevent atherosclerosis have focused on lowering LDL-C in patients at risk for the
disease. However, patients still have significant risk for developing CVD even when
LDL-C is reduced to healthy levels.3,4 Therefore, strategies that aim to reduce plasma
triglycerides are also required to eliminate hyperlipidemia and CVD risk.
Apolipoproteins reside on the outside of lipoproteins and can act as signaling
molecules and ligands, and are therefore important determinants of how lipoproteins
and the lipids inside of them are metabolized.5–7 Therefore, regulating the expression
and abundance of specific apolipoproteins is a method by which pharmaceutical and
dietary therapies can manage and direct lipid metabolism and moderate the risk of
cardiovascular disease. Apolipoprotein C-III (apoC-III) is a small protein produced
primarily by the liver and intestine.8,9 ApoC-III is secreted from these tissues on
triglyceride-rich lipoproteins (TRLs).10–12 The presence of apoC-III on lipoproteins
increases the resident time of these particles in circulation primarily by inhibiting uptake
of TRLs and their remnants by the hepatic low-density lipoprotein receptor (LDLR).13–15
In humans, plasma apoC-III levels are independently associated with both an increase
in plasma triglycerides and CVD risk.16,17 In the liver, the apoC-III protein promotes lipid
loading onto nascent VLDL and enhances VLDL assembly and secretion.18,19 In
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contrast, intestinal apoC-III causes retention of unesterified dietary lipid within the
enterocyte and a delay of triglyceride secretion into lymph.20
Factors that influence apoC3 gene expression in the liver have been well
researched, however, it is unknown how apoC3 is regulated in the intestine. In the study
presented herein, we aimed to determine if intestinal apoC3 is responsive to the same
dietary components and metabolites as hepatic apoC3. We use primary murine
enteroids, Caco-2 cells, and dietary studies in wild-type mice to test the effect of
glucose, insulin, and fat on hepatic and intestinal apoC-III expression.
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Chapter 1: Review of Literature
1.1 DEVELOPMENT OF CARDIOVASCULAR DISEASE
	
  
Cardiovascular disease (CVD) is the leading cause of death in both the United
States and globally.1 CVD is an umbrella term for a number of conditions that affect the
heart and blood vessels, such as coronary artery disease (CAD), myocardial infarction
(MI), and stroke. CVD tremendously affects both industrialized and unindustrialized
countries; approximately 17.7 million or 31% of deaths worldwide occur from CVD
related causes.1 Non-modifiable risk factors for CVD include genetic predisposition,
age, gender, ethnicity, and socioeconomic status. However, the majority of risk factors
for CVD, such as, hypertension, hyperlipidemia, type 2 diabetes, smoking, and stress
are modifiable and can be improved with diet and lifestyle interventions.1,21,22
Hyperlipidemia is central to pathophysiological development of atherosclerosis,
the key component of CAD. During the development and progression of atherosclerosis,
arteries narrow and harden due to the accumulation of lipid and fibrous elements.2 This
lipid accumulation occurs when oxidized low-density lipoprotein (LDL) particles are
taken up by the vascular endothelium and macrophages are recruited to the site of
injury. These lipid-laden macrophages are known as ‘foam cells.’ Foam cells become
problematic when smooth muscle cells (SMCs) of the media migrate into the intima and,
with extracellular matrix, form a fibrous cap that encloses a necrotic core of lipid-rich
cells.2 These calcified arterial plaques cause stenosis that impedes oxygen-rich blood
flow, and upon further injury to the luminal surface of the vessel, can rupture and cause
compete occlusion resulting in myocardial infarction or stroke.
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Given the central role of LDL-cholesterol in development atherosclerosis,
lowering LDL-C has been a central objective in the battle against CVD. In 1984, The
Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT) reported that
use of the cholesterol-lowering, bile acid sequestrant, cholestyramine, in middle-aged
men with primary hypercholesterolemia significantly reduced plasma cholesterol which
resulted in a significant decrease in the incidence of coronary heart disease in the
experimental group.23 With the advent and widespread use of more potent cholesterolreducing medications known as HMG-CoA reductase inhibitors, or statins, which lower
plasma cholesterol by interfering with the rate-limiting step of endogenous cholesterol
synthesis, research studies have been able to more effectively test the hypothesis that
reducing cholesterol significantly reduces CVD occurrence. Indeed, several metaanalyses of randomized controlled trials have reported that statins significantly reduce
all-cause mortality, combined fatal and non-fatal CVD and CHD events and stroke.24–27
Despite the impressive impact of cholesterol-lowering therapies on CVD risk, a
troublingly large number of patients still have residual risk for CVD despite optimal LDLC reduction.28 For example, even one of the most important randomized control trials
that demonstrated the success of statins in prevention of CVD-related events, The
Scandinavian Simvastatin Survival Study (4S), reported that 19% of people in the
simvastatin-treated group had one or more major coronary events in the 5.5 year followup period.29 These data and others like them, suggest significant residual risk even for
patients being treated with cholesterol-lowering drugs. Strategies that target the
reduction of LDL-C as a means to reduce morbidity and mortality from CVD-related
causes are not wholly effective, and hence, investigation into additional methods to
	
  

4	
  

eliminate CVD occurrence is warranted.
1.2 ANOTHER TARGET FOR REDUCING CVD RISK
Elevated plasma triglyceride level is the other detrimental, component of
hyperlipidemia. Nearly half a century ago JL Goldstein, AG Motulsky et al. asserted that
hypertriglyceridemia might be as significant a risk factor for coronary atherosclerosis as
hypercholesterolemia.3 In their study of 500 fasting survivors 3 months post myocardial
infarction, they reported that hypertriglyceridemia with (7.8%) or without (15.6%)
accompanying elevation in cholesterol levels was three times more common in
survivors than a high cholesterol level alone (7.6%).3 This incidence of hyperlipidemia
without hypercholesterolemia may account for the residual risk for CVD despite
cholesterol-lowering interventions, and underlies the importance of studying TAG and
the metabolism of triglyceride-rich lipoproteins that carry TAG throughout the body.
Indeed, hypertriglyceridemia has since emerged as an independent risk factor for CVD.
Two separate prospective studies, the Cholesterol and Recurrent Events (CARE) trial in
the United States, and The Copenhagen City Heart Study in Denmark, reported that
non-fasting plasma triglyceride level is a strong and independent predictor of future
myocardial infarction, ischemic heart disease, and death in both normo- and hypercholesterolemic men and women. 4,30
Apolipoproteins, with the exception of apo-B which provides more of a structural
framework for the particle, are proteins that reside on the outside of lipoproteins.
Lipoproteins like chylomicrons, VLDL, LDL, IDL, and HDL, carry lipids and cholesterol
through the aqueous environment of the blood under their phospholipid coat.7
Apolipoproteins can act as signaling molecules and ligands, and their placement on the
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outside of lipoproteins makes them important determinants of how lipoproteins and their
lipid cargo is metabolized.5–7
Apolipoprotein C-III links hypertriglyceridemia with increased CVD risk. ApoC-III
is a small, 79 amino acid protein produced predominantly by the liver and small
intestine, and is exported on the lipoproteins from these organs: VLDL and
chylomicrons, respectively.8,9 Apo C-III is a key determinant in how, and how quickly,
triglyceride-rich lipoproteins are exported into plasma and catabolized by peripheral
tissues. The protein is exchangeable in plasma, and therefore can migrate amongst
different types and species of lipoproteins.31 The presence of apoC-III on lipoprotein
particles delays their catabolism and prolongs the period of time lipoproteins remain in
circulation.32 Hence, not surprisingly, plasma abundance of apoC-III directly correlates
with plasma triglyceride levels.33 Additionally, a high concentration of apoC-III on VLDL
and LDL, independent of plasma triglyceride level, is a measure of coronary heart
disease risk.34 Given the increased risk of CVD incidence and adverse cardiovascular
events that accompanies elevated plasma triglycerides, and the atherogenicity of apoCIII itself, the ability to strategically manipulate expression of apoC-III is a promising tactic
to combat CVD occurrence.
1.3 FUNCTIONS OF APOC-III
Effect of apoC-III on circulating TAG levels
The level of apoC-III expression directly correlates to triglyceride levels in both
rodent models and humans. During the development of a human apoC3 transgenic
mouse model, Breslow et al. found that mice lines with 100 copies of the gene were
severely hypertriglyceridemic, while other lines with only a one to two copies of the gene
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produced less apoC-III protein and had only mildly elevated triglyceride levels.35 This
gene dose effect is similarly apparent in humans; humans heterozygous for a defective
apoC3 allele, such as the Lancaster Amish who are carriers of the null R19X mutation in
the apoC3 gene, produce half as much apoC-III as those without the mutation.36 These
heterozygous carriers of the mutant gene also have a corresponding decrease in
plasma triglycerides and coronary artery calcification, which is a marker of subclincal
atherosclerosis.36 Additionally, other genome-wide association studies (GWAS) have
uncovered several distinct populations with rare mutations that affect ApoC3 function.
These loss-of-function mutations in ApoC3 are associated with hypotriglyceridemia and
confer nearly complete cardioprotection. 37–40

Interference with TRL lipolysis and clearance
Several mechanisms by which apoC-III elevates plasma TAG have been
established. In 1972, Brown and Baginsky first described apoC-III as an inhibitor of
lipoprotein lipase (LPL),9,41 which reduced the lipolysis and unloading of lipid into
peripheral tissues, therefore keeping more TAG retained in large lipoproteins longer.
Yet a small clinical study that tested the effect of the apoC-III specific antisense
oligonucleotide (ASO), volanesorsen, in patients with a genetic LPL deficiency and
resultant chylomicronemia, resulted in significant reductions of plasma TAG in these
patients.42 These patients do not have functioning LPL but their plasma TAG levels
were still reduced when apoC-III expression was ablated, suggesting that the inhibition
of LPL by apoC-III is not the mechanism, or at least not the central mechanism, by
which apoC-III raises circulating triglyceride levels. This trial indicates that apoC-III
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interferes with another mechanism by which lipid is cleared from plasma, independent
of LPL.15,42
Likely the most significant mechanism by which apoC-III increases plasma TAG,
is through its interference with hepatic receptors that clear TRLs and their remnants
from circulation.15 Gordts and Esko et al.15 also used the ApoC-III ASO volanesorsen,
which binds apoC-III mRNA and targets it for degradation, to reduce apoC-III levels in
several distinct mutant mouse lines, including: low-density lipoprotein receptor (LDLR)
knockouts, LDLR-related protein 1 (LRP1) knockouts, and heparan sulfate proteoglycan
receptors (HSPGs) knockout mice, as well as additional sets of mice who were double
knockouts for a pair of receptors. The results of their experiments show that apoC-III
ASO treatment lowered plasma TAG in mice lacking hepatic HSPG receptors, LDLR, or
LRP1. The drug also reduced TAG in animals with combined deletion of the genes
encoding HSPG receptors and LDLRs or LRP1. However, apoC-III ASO treatment did
not reduce triglycerides in mice who were knockouts of both	
  LDLR and LRP1,
suggesting that apoC-III primarily elevated plasma triglyceride levels by impeding
hepatic TRL clearance via these receptors.15
There is also evidence that apoC-III inhibits hepatic TRL uptake by interfering
with or displacing apoE, a major ligand by which liver receptors clear lipoproteins.
Hypertriglyceridemic, human apoC-III transgenic mice accumulate triglyceride-rich,
VLDL-like particles carrying abundant apoC-III and lacking apoE.14 Furthermore, human
lipoprotein kinetic studies conducted by the Zheng et al. have shown that patients with
hypertriglyceridemia produce 3-times more VLDL without apoE but with apoC-III, than
do normolipidemic controls.43 Additionally, the apoC-III-containing apoB lipoproteins
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devoid of apoE were removed significantly more slowly from circulation than those with
both apo C and E.43

Promotion of VLDL assembly and secretion
In rat hepatoma McA-RH7777 cells transfected with human apoC-III and cultured
in lipid-rich conditions, apoC-III increases VLDL-TAG secretion in a gene dosedependent manner.19 ApoC-III seems to promote lipid-loading into VLDL particles in the
liver by functioning in conjunction with microsomal triglyceride transfer protein (MTP).44
Transfection of human apoC-III into these hepatoma cells significantly increased the
mRNA expression and activity of MTP.18 In the initial stages of VLDL synthesis,
lipidation of hepatic apoB begins immediately as the apoB protein is translated. 45
However, MTP is crucial for the continued lipidation of the nascent lipoprotein and is
necessary to avoid degradation of lipid-poor apoB.46 MTP is also required for later
stages of lipid loading, in the recruitment of triglyceride into the endoplasmic reticulum
and Golgi compartments for VLDL assembly.44,47 Labeling of apoC-III protein with
[35S]methionine/cysteine in the same experiment using human apoC-III- expressing
McA-RH7777 cells, showed that the majority of apoC-III was distributed within TAG-rich
microsomal lumen fractions.19 This data may suggest that apoC-III works in conjunction
with MTP to partition TAG substrate into the endoplasmic reticulum and Golgi for VLDL
assembly.19,44 In support of the idea that apoC-III promotes VLDL lipid loading and
secretion, is the finding that subjects with missense mutations in the ApoC3 gene that
code for its lipid-binding domain have unusually low plasma triglycerides.36,48,49
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Atherogenicity of apoC-III
ApoC-III is a potent regulator of plasma triglyceride levels, but research has also
demonstrated that apoC-III is proatherogenic aside from its role in elevating triglyceride
concentration. In a prospective study of 2 populations: the female participants in the
Nurses’ Health Study (NHS) and the male participants in the Health Professionals
Follow-up Study (HPFS), Mendivil & Sacks (2011)50 sought to determine if increased
concentrations of VLDL and LDL with apoC-III is associated with increased CVD risk
versus VLDL and LDL devoid of apoC-III. The subjects in the two populations were free
of CVD at the start of the study. Researchers found that concentrations of LDL with
apoC-III positively correlate with risk of coronary heart disease in multivariable analysis
that included the ratio of total cholesterol HDL cholesterol, LDL cholesterol, apoB,
triglycerides, or HDL cholesterol and other risk factors.50 While several other studies
have implicated increased apoC-III concentrations with the development and
progression of atherosclerosis 51–54 and the incidence of adverse cardiovascular events
associated with CVD,34,50,55,56 the molecular mechanisms by which apoC-III functions to
promote atherosclerosis are still poorly understood.

Role of apoC-III in the intestine
Research has focused on the role of apoC-III in the liver and its role on plasma
lipoproteins. Comparatively, little is known about the role of apoC-III in the small
intestine. ApoC-III protein is present on chylomicrons secreted from the intestine. ApoCIII mRNA expression in the duodenum is approximately 30% of the amount produced in
the liver, with the most proximal section of the small intestine producing the most and
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the ileum the least.20 Human apoC-III transgenic mice express about 5 times more
apoC-III mRNA with the same tissue distribution of apoC-III as wild-type mice, hence
this model can also be used to study apoC-III overexpression and its consequences in
the intestine.20
Emerging evidence suggests that the role of apoC-III in intestine differs
significantly from that in the liver. Contrary to apoC-III’s function of increasing VLDL
assembly and secretion in the liver, 19 intestinal apoC-III appears to inhibit TAG
secretion into lymphatic circulation. Kohan and Wang20 reported that human apoC3
transgenic mice infused intraduodenally with radiolabeled lipid demonstrated delayed
uptake of the lipid from the intestinal lumen, impaired esterification of FFA and MAG into
TAG, and decreased secretion of lipid from the intestinal enterocytes into lymph.20 In
line with this finding, intestinal organoids prepared from intestinal stem cells from human
apoC-III transgenic mice secrete smaller, less dense chylomicrons with less TAG.
These data suggest that the function of intestinal apoC-III and the physiological
outcome of expressing intestinal apoC-III, are both entirely opposite to their function in
the liver.
1.4 REGULATION OF APOC3 IN THE LIVER & INTESTINE
Scarce data exist regarding what factors regulate apoC3 gene expression in the
intestine, but a number of nutrients and metabolites have been shown to regulate
hepatic apoC3 via action on various transcription factors51. ApoC-III may contribute to
the development of diabetic dyslipidemia in the insulin resistant state because its
expression in the liver is upregulated by glucose and downregulated by insulin.57 In
primary rat hepatocytes and immortalized human hepatocytes, glucose increases apoC	
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III transcription by activating transcription factors HNF-4α and ChREBP, which bind Eboxes found in the proximal C3P footprint in the apoC3 promoter.57 FXR and PPARα
agonists decrease hepatic expression of apoC3 because FXR and PPARα can displace
HNF-4α from its location in the apoC3 enhancer region or the CP3 footprint.57,58
Insulin’s impact on hepatic apoC3 expression is primarily attributed to the
transcription factor Forkhead box O1 (FoxO1). When active, FoxO1 binds to the apoC3
promoter and stimulates transcription.59 FoxO1 is deactivated by insulin via signaling
through the insulin receptor substrate (IRS) which causes phosphorylation of Foxo1
through the PI3K/Akt pathway and consequent nuclear exclusion.60,61 Streptozotocintreated mice, which model an insulin deficient diabetic state, have an approximately 1.5
fold increase in hepatic apoC-III mRNA levels, accompanied by elevated plasma
glucose and triglycerides.62 Hepatic apoC-III mRNA expression can be reduced by
nearly 60%, and glucose and triglyceride levels normalized, when the animals are
treated with insulin.62 Similarly, HepG2 cells transfected with an apoC-III reporter
construct demonstrate a dose-dependent downregulation of apoC-III transcription in
response to insulin.62 In primary rat hepatocytes transfected with FoxO1 cDNA by
adenovirus, FoxO1 stimulates apoC-III mRNA expression and the hepatocytes exhibit a
dose-responsive decrease in apoC-III transcription upon treatment with insulin.59
Deletion or mutation of the FoxO1 binding site in the apoC-III promoter ablates this
response to insulin and the corresponding FoxO1-mediated stimulation of apoC-III gene
expression.59
FoxO1 has also been implicated in the regulation of apoC-III gene expression in
the intestine, but only in one study. In the same study mentioned above, by Altomonte
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and Dong et al,59 in which researchers delivered FoxO1 cDNA to primary rat
hepatocytes, they also conducted an experiment on Caco-2 cells overexpressing
constitutively active FoxO1. Like the hepatocytes, Caco-2 cells overexpressing FoxO1
also produced more apoC-III mRNA and this expression was attenuated with insulin
treatment. 59 However, the experiment did not examine the effect of insulin on Caco-2
cells that were not vector-transduced --those with only basal, physiological levels of
FoxO1. Hence, the experiment did not determine if FoxO1 is a central regulator of
apoC-III expression in the intestine.
Hepatic apoC-III gene expression appears to be moderated in part by the action
of PPARα on FoxO1. Fibrates, which are PPARα agonists, are known to downregulate
the expression of apoC-III in the liver and to reduce plasma concentration of apoC-III in
both animal and human studies.63 PPARα inhibits FoxO1 binding to the insulinresponsive element in the apoC3 gene.64 Long chain, n-3 polyunsaturated fatty acids
(PUFAs) like docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), which are
found in fish and algal oils, are ligands that trigger PPARα activation.65–67 In the liver,
DHA suppresses the expression of FoxO1 and its target genes which include MTP,
glucose-6-phosphatase, insulin-like growth factor binding-protein 1 (IGFBP1) and apoCIII.68 Hence, this activation of PPARα, and subsequent deactivation of FoxO1 which
results in less apoC-III expression in the liver, may contribute to the hypolipedemic
effect of fish oil supplementation in humans.69–73
1.5 CONCLUSION
ApoC-III is a potent modulator of plasma triglyceride levels and abundance of this
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apoprotein in human plasma is proatherogenic.16,34,74 Given the widespread impact of
CVD worldwide, new and effective therapies to reduce CVD risk are necessary. ApoCIII promotes hypertriglyceridemia by promoting VLDL assembly in the liver and
decreasing clearance of TRLs from circulation.15,19 Glucose, insulin, and dietary n-3
fatty acids have an impact on hepatic apoC-III expression.57,59,68 However, considerably
less is known about the role and regulation of apoC-III in the intestine. Interestingly,
what is known about the function of intestinal apoC-III is paradoxical to its role in the
liver; intestinal apoC-III delays secretion of chylomicrons and their TAG cargo.20,75
ApoC-III can be a valuable target in reducing CVD risk, however given the differences
between hepatic and intestinal apoC-III, more research regarding the tissue-specific
function of this apoprotein is warranted.
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Chapter 2: Key differences between apoC-III regulation and expression in
intestine and liver.

This chapter is presented in its previously published format.
West G, Rodia C, Johnson Z, Li D, Dong H, Kohan AB. Key differences between apoCIII regulation and expression in intestine and liver. BBRC. (2017)
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INTRODUCTION
Apolipoprotein C-III (apoC-III) is expressed in both liver and the intestine, and is
secreted from these tissues on triglyceride-rich lipoproteins (TRLs)10–12. ApoC-III was
first established as an inhibitor of lipoprotein lipase (LPL), and it has been more recently
established that the most robust role of apoC-III is likely its inhibition of hepatic lowdensity lipoprotein receptor (LDLR)13–15. These inhibitory actions of apoC-III increase
the plasma residence time of TRLs and their remnants. In humans, plasma apoC-III
levels are independently associated with both an increase in plasma triglycerides and
CVD risk 16,17.
Elevated plasma triglycerides are an independent risk factor for cardiovascular
disease (CVD), the leading cause of mortality in the United States. The importance of
apoC-III in human CVD incidence has been well-established: in patients with the R19X
null mutation in apoC-III, CVD incidence is significantly reduced, whereas in patients
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with elevations in plasma apoC-III, CVD incidence in robustly increased 34,36–38,74,76.
We have recently established an intestinal role for apoC-III. We find that
overexpression of apoC-III results in a delay in dietary lipid absorption and causes the
secretion of smaller chylomicrons 20,75. This is paradoxical to both the triglyceride-raising
role apoC-III plays in the plasma, and cell culture data suggesting that intracellular
apoC-III promotes the synthesis and secretion of larger, more triglyceride-rich VLDL
from the liver 18,48.
Research on the mechanisms that control apoC-III gene expression has focused
on hepatic apoC-III. In primary rat hepatocytes, glucose upregulates apoC-III
transcription by activating transcription factors HNF-4α and ChREBP, which bind Eboxes found in the proximal C3P footprint in the apoC-III promoter 57. Conversely,
insulin down-regulates hepatic apoC-III through phosphorylation and nuclear exclusion
of the transcription factor Forkhead box O1 (FoxO1)77. Furthermore, hepatic apoC-III
mRNA is significantly elevated in mice with streptozotocin-induced insulin deficiency 62.
In liver, polyunsaturated fatty acids inhibit FoxO1 expression and its target genes in
liver, including apoC-III 68.
While the regulation of hepatic apoC-III gene expression has been well studied,
the factors that regulate apoC-III in the intestine are still largely unknown. In Caco-2
cells overexpressing constitutively active FoxO1, apoC-III mRNA is significantly
increased 59. However, little is known about the role of physiological levels of FoxO1 in
apoC-III regulation in the intestine. Unlike hepatic apoC-III, which is inhibited by long
chain polyunsaturated fatty acids 68, it is unknown how intestinal apoC-III expression
responds to dietary fat.
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Since we have previously established that the role of apoC-III in the intestine
differs significantly from that in the liver, the purpose of this study is to establish the in
vivo regulation of intestinal apoC-III. In this work, we establish that intestinal apoC-III
expression is not responsive to dietary fat or glucose, and in primary murine enteroids
and Caco-2 cells, apoC-III expression is not inhibited by insulin. We also show that in
contrast to the liver, intestinal FoxO1 expression is very low and apoC-III is not
regulated coordinately with FoxO1 target genes in the intestine. Finally, intestinal apoCIII expression does not change in response to a western diet challenge, whereas we
confirm previous studies showing that hepatic apoC-III expression is stimulated by
western diet. Our findings support the notion that though the liver and intestine share
TRL synthesis and secretion, they do not share identical regulatory pathways for
proteins that are involved TRL synthesis and secretion.
METHODS
Animals. Male and female C57Bl/6J mice (Jackson Laboratories, Bar Harbor, ME), 812 weeks old, were housed 3-4 per cage in a temperature-controlled (23 ±1°C) vivarium
on a 12-h light-dark cycle. Mice received free access to water, and were maintained on
either standard rodent chow (Teklad global cat.#2918) or western diet (42% kcal from
fat, 0.2% cholesterol by weight) from Envigo TD.88137, for 12 weeks. Animals were
sacrificed under isoflurane anesthesia following an overnight fast. For gavage studies,
mice continued on chow diet and were gavaged at the same time daily for one week
with saline, corn oil (60µL), or corn oil (60µL) with glucose (135µL of 5M glucose). Each
gavage was made isovolumetric (195µL) using saline. Mice were fasted overnight on
the last day before they were sacrificed. The next morning, plasma, liver, and small
	
  

17	
  

intestine were collected, flash frozen in liquid nitrogen, and stored at -80°C until
analysis. All animal procedures were performed in accordance with the University of
Connecticut Internal Animal Care and Use Committee and in compliance with the
National Institutes of Health Guide for the Care and Use of Laboratory Animals.

Caco-2 cells. Caco-2 cells were used for experiments at 17d post-confluence. As
described by Nauli et al. 78, this protocol produces the most abundant apoB-lipoproteins.
Cells were kept at 37°C with 5% CO2 in Eagle’s Minimum Essential Medium with LGlutamine (Corning Cellgro #10-010-CM), 10% Fetal Bovine Serum (FBS), 1% Lglutamine, penicillin/streptomycin, sodium pyruvate, non-essential amino acids, and 1.5
g/L sodium bicarbonate. For experiments, cells were serum starved overnight prior to
treatments. To measure the effect of varying concentrations of glucose and insulin, we
incubated cells in low glucose DMEM (1g/L glucose) and high glucose DMEM (4.5g/L)
with and without human insulin (final concentration 80nM, Sigma, St. Louis, MO. cat#
I9278). Cells were treated with 2mL of treatment media in each well for 24 hours. After
24 hours, media was collected and cells were washed with ice cold 10% phosphatebuffered saline (PBS). Cells were incubated in fatty acid growth medium for 4 hours
before they were washed with ice cold 10% PBS (phosphate-buffered saline). Fresh
media was added to each well and plates were incubated for 24 hours before protein
and RNA analysis.

Enteroid Culture. We isolated intestinal stem cells (ISCs) from crypts as described
previously 75,79. Primary crypts were isolated from WT mice, age 8-12 weeks. Crypts
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were placed in Matrigel; following 30min polymerization, crypts were treated with 500µl
of enteroid medium (Advanced DMEM/F12 (12634- 010; Life Technologies, Carlsbad,
CA, USA) with 2mM L-Glutamine, 10mM HEPES, 100U/mL penicillin/100µg/mL
streptomycin and 1× N2 and 1× B27 supplements,lus 1µL of R-spondin 1 (250µg/mL),
1µL of Noggin (50µg/mL) and 0.25µL of EGF (100µg/mL). Media was replaced every 3
days. For treatment with lipid, mature enteroids were dissociated from Matrigel by
washing with ice cold DPBS, followed by a 150x g spin for 10 min. After removing the
supernatant, the intact enteroids were then placed in 1ml of treatment media containing
400µM OA: BSA or BSA alone, or enteroid growth media containing glucose, or
enteroid growth media containing insulin; all media contained Rho-kinase inhibitor. The
enteroids were very gently opened by pipetting up and down with a p1000 pipette,
followed by incubation with the lids open in a 37° 5% CO2 incubator for 2 hours. After 2
hours, the enteroids were centrifuged at 150 x g for 10 minutes and the supernatant
collected. Following an additional wash and centrifuge with 1ml of DPBS (which was
added to the media samples), the enteroids were resuspended in 1ml of enteroid growth
media and placed back in the incubator for 6 hours, with the lid to their tubes left open
for gas exchange. The media and cell pellet were then collected via centrifugation at
150 x g for 10 minutes.

Preparation of BSA-bound FFA. To test the effect of dietary fatty acids on apoC-III
expression, we treated the enteroids and Caco-2 cells with BSA-bound FFA. Oleic acid
(Nu-Check Prep) was prepared as 4mM stock solutions in complex with fatty acid-free
bovine serum albumin (BSA) at a 1:4 molar ratio and the stock contained butylated	
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hydroxytoluene 0.1% (19). Cells not receiving the 400µM OA: BSA complex were
treated with an equivalent amount of BSA.

Immunofluorescence. Enteroids were grown in chamber glass wells and fixed with
4% PFA in PBS for 30 min, followed by 50mM NH4Cl in PBS for 30min to quench
autoflorescence. They were washed 5X with PBS, followed by 0.5% Triton X-100 in
PBS for 30min, and then were blocked in 5%BSA in PBST overnight at 4°C. Fixed
enteroids were incubated with primary antibody against apoB (1:100, Abcam #ab20737)
for 3 days at 4°C. After 5 washes with PBS, samples were incubated with secondary
Alexa 488 (1:500, Abcam #ab150065) overnight at 4°C. Enteriod were also stained with
nuclei stain Hoechst 33342 (10µg/ml in PBST). Images were captured by confocal
microscopy use NiKon A1R (20X and 60X water objective lens).

Gene Expression via RT-qPCR. RNA was isolated from washed cells (Caco-2 and
enteroids) and isolated tissues (gavage and western diet mice) according to Trizol
product instructions. RNA pellets were dissolved in nuclease-free dH2O before
concentration was determined using a BioTek Epoch spectrophotometer. cDNA was
synthesized using 2 µg of RNA in a iScript cDNA synthesis kit (BioRad, #1708890).
Quantitative real-time polymerase chain reaction (PCR) was conducted using the CFX
Connect real time system (BioRad) and iTaq SYBR® Green Supermix (Bio-Rad).
Human RPLPO was used as the reference gene in the Caco-2 studies. Mouse
cyclophilin was used as the reference gene in dietary studies. Gene expression was
calculated using the comparative threshold cycle method.
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Plasma lipid and glucose analysis. To measure plasma lipids, we used the Randox
(catalog # TR210) triglyceride assay and total cholesterol assay (catalog # CH200), in
mice that had been fasted overnight (6pm-6am). Plasma glucose was also measured in
the fasted state, using liquid glucose oxidase assay by Pointe Scientific, Inc (Canton, MI
G7521-120).

Statistics. All data are presented as the mean ± the SEM. Statistics were performed
using GraphPad Prism (version 6.0). The differences were analyzed by Student’s t-test.
Analyses of more than 1 experimental group, compared to control tissue, were analyzed
by one-way ANOVA. Differences were considered significant at P < 0.05.

RESULTS
In murine intestinal enteroids, apoC-III is not regulated by glucose, insulin, or
fatty acid.
Although previous studies have determined that insulin 77, glucose 57, and fatty
acids 68 regulate apoC-III expression in the liver, little is known about intestinal apoC-III
regulation. To determine how intestinal apoC-III is regulated, we utilized a primary
intestinal enteroid culture system. Primary enteroids are derived from WT mouse
duodenal and jejunal crypt stem cells, and we have previously established that this
tissue culture system significantly improves upon Caco-2 cells as a model for dietary fat
absorption and chylomicron secretion 75. In Fig. 1A we show the 3-dimensional
architecture of mature primary enteroids, which apoB-positive cells surrounding a
central lumen (reflecting the in vivo architecture of the intestine). Because hepatic
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apoC-III is regulated by both glucose and insulin, we tested the hypothesis that these
conditions may also regulate intestinal apoC-III. Treatment of enteroids with glucose or
insulin did not alter intestinal apoC-III expression in the enteroids (Fig. 1B, 1C). Since
apoC-III is secreted from enterocytes on chylomicrons (a process that is stimulated by
dietary fat), we hypothesized that intestinal apoC-III would also be responsive to dietary
fatty acids4. After incubation of primary enteroids with oleic acid (Fig. 1D), we
determined that intestinal apoC-III mRNA expression is not stimulated by this fatty acid.
We confirmed these results in Caco-2 cells, since it has been previously shown that
Caco-2 cells transfected with FoxO1, have decreased apoC-III expression in response
to increasing insulin concentrations 77. As in our enteroid culture studies, incubation with
glucose, insulin, or oleic acid did not alter apoC-III expression in Caco-2 cells. Taken
together, these results indicate in both primary intestinal enteroids and Caco-2 cells,
apoC-III mRNA is uniquely non-responsive to changes in glucose, insulin, or fatty acids.
This contrasts with the well-established regulation of hepatic apoC-III by these factors.
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Fig. 1: ApoC-III mRNA expression in primary murine enteroids or Caco-2
cells is not affected by treatment with glucose, insulin, or oleic acid. (A)
Primary duodenal murine enteroids were cultured for 10 days until they reach
maturity with cells arranged around a central lumen, and a basolateral face
towards the media. Enteroids were fixed and stained with Hoechst stain (blue:
nuclei) and anti-apoB (green) to visualize the 3D architecture of the enteroid
culture. Enteroid and Caco-2 cell (cultured for 17d post-confluence) apoC-III
mRNA expression in response to (B) glucose, (C) insulin, (D) BSA bound oleic
acid. Bars represent mean apoC-III expression ±SEM, n=3-7.
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FoxO1 expression is low in the intestine
Since we saw no changes in intestinal apoC-III expression in response to
glucose were observed, insulin, and fatty acid, we decided to investigate whether
intestinal apoC-III is a target of FoxO1 inhibition in the intestine. We find that in
comparison to hepatic FoxO1 mRNA expression, its expression in duodenal enteroids is
low to undetectable (Fig 2A). We also find that treating primary enteroids with insulin, in
the presence of either low or high glucose, does not change FoxO1 mRNA expression
(Fig. 2B).

Fig. 2: FoxO1 mRNA expression in murine enteroids. (A) FoxO1 mRNA
expression in WT mouse liver (fasted) and mature murine duodenal enteroids
FOXO-1, normalized to cyclophilin. (B) FoxO1 mRNA expression in mature
murine duodenal enteroids when treated for 6-h with insulin, in both low glucose
(5.5 mM) and high glucose (25 mM) media. Bars represent mean apoC-III
expression ±SEM, n=3-5.
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In vivo, intestinal apoC-III mRNA expression is not regulated in response to
gavaged lipid and glucose.
To further explore the differences in acute hepatic and intestinal apoC-III
regulation in response to diet, we took an in vivo approach. We gavaged WT mice daily
for one week with either saline, corn oil, or corn oil l plus glucose. After the treatment
period, hepatic apoC-III expression increased with both the corn oil and corn oil +
glucose treatment, confirming that hepatic apoC-III expression is regulated by these
dietary nutrients (Figure 3A). In contrast, intestinal apoC-III expression did not change
under any treatment condition, further corroborating the cell culture findings (Figure 3A).
Since FoxO1 is regulated by both expression, phosphorylation, and nuclear exclusion,
we measured the expression of canonical FoxO1 target gene, insulin-like growth factor
binding protein 1 (IGFBP-1), in response to the gavaged nutrients (Fig. 3B). We find that
in the liver, corn oil plus glucose robustly stimulate IGFBP-1, in parallel with apoC-III
expression (and suggesting that FoxO1 is active under these conditions). In contrast,
IGFBP-1 is non-detectable in the intestine in response to gavage.
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Fig 3. Duodenal mRNA expression of FoxO1 target genes, apoC-III and
IGFBP-1, are not changed after a week-long daily gavage. (A) ApoC-III mRNA
expression in liver or intestine in response to 1 week of daily gavages of
isovolumetric saline, corn oil (60µL), or corn oil (60µL) with glucose (135µL of 5M
glucose). (B) IGFBP-1 mRNA expression in liver or intestine of gavaged mice. Bars
represent ±SEM of normalized mRNA expression, *P<0.05 versus saline, not
detectable (nd), n=3-4 WT mice per gavage group.
	
  

Western diet stimulates hepatic apoC-III expression but does not alter intestinal
apoC-III expression.
Western diet is known to increase plasma triglycerides, and the expression of
genes in the liver that increase CVD risk. It is unknown to what extent the increase in
plasma triglycerides are due to an increase in intestinal or hepatic apoC-III. We
challenged WT mice for 12 weeks with western diet, consisting of 42% calories from
butterfat and 0.2% total cholesterol, and compared these to mice provided standard
chow diet. In response to western diet, mice have a significant increase in body weight
compared to chow-fed controls (Fig. 4A). As expected, WT mice on the western diet
had an approximately 2-fold increase in plasma TAG (53.15mg/dL versus 24.37mg/dL;
p=0.01. Fig. 5B) and an approximately 3-fold increase in plasma cholesterol (230mg/dL
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versus 77mg/dL; p=0.01. Fig.4C). Plasma glucose was not significantly increased in
response to the western diet (Fig. 4D). Suggesting that the mice do not lose insulintolerance after the 12 week western diet.

Fig. 4: A 12 week western type diet alters plasma lipids and increases body
weight compared to a chow diet. (A) Fasting plasma triglycerides in chow and
WTD-fed mice. (B) Terminal body weights in grams. (C) Fasting plasma total
cholesterol. (D) Fasting blood glucose blood glucose levels after the diet concluded.
Data represent mean ± SEM. *P<0.05, ***P<0.001, n=5 per diet.

In response to the western diet, hepatic apoC-III expression is significantly higher
compared to chow-fed controls (Fig. 5A), and both hepatic FoxO1 mRNA and its
canonical target gene, IGFBP1, are also increased in parallel to apoC-III (Fig. 5B, 5C).
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In contrast to these hepatic changes, western diet did not alter the expression of
intestinal apoC-III (Fig. 5D). Interestingly, intestinal FoxO1 expression was decreased in
the intestine and IGFBP1 is not changed (Fig. 5E, 5F). These data confirm that apoC-III
is not regulated in the intestine, as it is in the liver, and strongly suggests that FoxO1 is
not responsible for intestinal apoC-III mRNA regulation, in contrast to its importance in
regulating apoC-III in the liver.
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Fig. 5: Western diet increases hepatic but not intestinal apoC-III. Hepatic
mRNA expression of (A) apoC-III, (B) FoxO1 and (C) IGFBP-1 expression in chowfed versus WTD-fed mice. Intestinal expression of (D) apoC-III, (E) FoxO1 and (F)
IGFBP-1. Bars represent ±SEM of normalized mRNA expression, *P<0.05 versus
chow-fed, n=5/diet.
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DISCUSSION
Hepatic apoC-III regulation has been studied at length because of its importance
in triglyceride homeostasis and ultimately its role as an independent predictor of
cardiovascular disease incidence 44,50,59. Considerably less is known about the factors
that regulate intestinal apoC-III. In this work, we show that intestinal apoC-III expression
does not change in response to fatty acids, glucose, or insulin administration, in contrast
to hepatic apoC-III. Intestinal apoC-III is not sensitive to changes in FoxO1 expression
(which is itself very low in the intestine, as is FoxO1 target IGFBP-1), nor is intestinal
apoC-III responsive to the western diet, a significant contrast to hepatic apoC-III
stimulation during feeding with a western diet. These data strongly suggest that
intestinal apoC-III is not a FoxO1 target. These data support the idea that apoC-III is not
regulated coordinately with hepatic apoC-III, and establishes another key aspect of
apoC-III that is unique in the intestine and different from the liver.
In these studies, we have focused on dietary lipid and glucose, since these were
previously identified as major drivers of apoC-III expression in liver 59,77,80. Because we
have identified a unique consequence of apoC-III overexpression in the intestine (the
inhibition of dietary fat absorption coupled with altered chylomicron secretion)20,75, and
because regulation of apoC-III in Caco-2 cell culture is so far removed from in vivo
conditions that might regulate apoC-III, we wanted to establish the critical dietary factors
in the regulation of intestinal apoC-III.
Dong et al previously established that hepatic apoC-III is a target of FoxO1,
through the –498/–403 element in the APOC3 promoter 59. They showed that deletion of
this consensus IRE causes unrestrained apoC-III expression during insulin-resistance
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and diabetes, leading to hypertriglyceridemia. As part of their assessment of FoxO1 and
apoC-III, Dong et al also provide evidence from Caco-2 cells overexpressing
constitutively active FoxO1 that apoC-III expression is also under the control of FoxO1
in the intestine. They suggest that apoC-III is coordinately regulated in both intestine
and liver.
Instead of Caco-2 cells, here we have used primary murine enteroids, isolated
and cultured from duodenal and jejunal stem cells. We have previously established that
these duodenal enteroids absorb fatty acid and form triglyceride-rich chylomicrons,
which mirrors their origin in the small intestine. This primary culture system significantly
improves upon Caco-2 cells because of their 3D architecture, with enterocytes arranged
around a central lumen, and a basolateral surface facing the media. Therefore, the lack
of apoC-III regulation in response to individual stimuli in this culture system strongly
supports the idea that intestinal apoC-III, within the in vivo context, is not regulated by
dietary factors in parallel with the liver.
We find that FoxO1 expression in mouse intestine is extremely low, and
treatment with insulin changes this very slightly. This is in contrast to Dong et al.
However, our data support recent work by Accili et al. 81, who have established a role of
FoxO1 in the intestine in endocrine progenitor and serotonin-producing cells. Accili et al.
use immunohistochemistry for a detailed analysis of FoxO1 expression in the human
gut. They establish that FoxO1 is enriched in the crypt bottoms, and specifically colocalizes with serotonin (5HT)-positive endocrine (rather than absorptive enterocyte)
cells. Our data in intact mouse intestine supports this finding because we see such low
expression in whole tissue (endocrine cells are vastly outnumbered by enterocytes).
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Primary enteroids also maintain a small population of enteroendocrine cells,
which is likely the source of FoxO1 expression in our cultures. The restriction of FoxO1
to endocrine cells in the intestine would preclude it from directly regulating apoC-III
expression in the absorptive epithelium, though this does not necessarily mean that
endocrine cells don’t play an important role in modulating the enterocyte function.
Why does it matter that intestinal apoC-III in not regulated by western diet, or through
the action of FoxO1? Our findings are additional support for the notion that while the
liver and intestine share the role of triglyceride-rich lipoprotein synthesis and secretion,
they do not share identical regulatory pathways for proteins that are involved. Our data
also support the notion that apoC-III secretion from the intestine is under a unique set of
pressures. Whereas the liver can quite significantly change VLDL secretion rates in
response to the presence or absence of substrate and hormones, the intestine is less
labile in the face of dietary lipid, which is quickly and efficiently secreted in
chylomicrons. Therefore, our finding that apoC-III levels in the intestine do not change,
suggests that apoC-III is important for this physiological action of the intestine, and that
there is still room to identify factors that might inhibit apoC-III in this tissue for the
purposes of ameliorating its stimulatory role in plasma hypertriglyceridemia and CVD.
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Summary and Conclusions
Our work demonstrates that intestinal apoC-III is not regulated in vivo or in vitro
by glucose, insulin, or fat and is therefore not coordinately regulated with hepatic apoCIII, which responds to those factors. Furthermore, this study determines that FoxO1 is
not a regulator of intestinal apoC-III. Our lab has previously demonstrated that the
physiological function of intestinal apoC-III differs drastically from hepatic apoC-III.
Hence, both the regulation and role of intestinal apoC-III is distinctive from what we
know about apoC-III in the liver.

Future Directions
Given the importance of the digestive system in mediating the body’s interaction
with exogenous nutrients, the intestine is likely still an important mediator of CVD risk.
Since prior research by our lab has demonstrated that the physiological role of apoC-III
in the intestine differs from that in the liver, it may be possible that intestinal apoC-III can
favorably alter CVD risk. In the future, an organ-specific knockout of apoC-III will
delineate the precise role of apoC-III in each tissue. We also have yet to uncover why
apoC-III decreases TAG secretion from enterocytes and the precise machinery behind
that effect. And finally, this work does not support the hypothesis that FoxO1 regulates
apoC3 in the intestine. We did not uncover in this study the factors that regulate
intestinal apoC-III. Continued exploration of factors that regulate apoC-III expression in
the intestine are still necessary.
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